Journal Home
Search for

Volume 35, Issue 8, Pages 1358-1362 (August 2009)


View previous. 10 of 44 View next.

Complication and failure rates after corneal crosslinking

Tobias Koller, MD, Michael Mrochen, PhD, Theo Seiler, MD, PhDCorresponding Author Informationemail address

Received 20 December 2008; received in revised form 16 March 2009; accepted 16 March 2009.

Purpose

To evaluate the complication rate of corneal crosslinking (CXL) for primary keratectasia and to develop recommendations for avoiding complications.

Setting

Institut für Refraktive und Ophthalmo-Chirurgie, Zurich, Switzerland.

Methods

In a prospective study, eyes with verified progressive keratectasia had standard CXL. Preoperative and 6- and 12-month postoperative examinations included corrected distance visual acuity (CDVA), slitlamp evaluation, applanation tonometry, and Scheimpflug imaging (Pentacam). Statistical analysis included analysis of variance and the Mann-Whitney U test to detect risk factors for complications.

Results

The study evaluated 117 eyes of 99 patients; approximately 90% completed the 12-month follow-up. The complication rate (percentage of eyes losing 2 or more Snellen lines) was 2.9% (95% confidence interval, 0.6%-8.5%). The failure rate of CXL (percentage of eyes with continued progression) was 7.6%. Age older than 35 years and a preoperative CDVA better than 20/25 were identified as significant risk factors for complications. A high preoperative maximum keratometry (K) reading was a significant risk factor for failure. Sterile infiltrates were seen in 7.6% of eyes and central stromal scars, in 2.8%.

Conclusions

Results indicate that changing the inclusion criteria may significantly reduce the complications and failures of CXL. A preoperative maximum K reading less than 58.00 diopters may reduce the failure rate to less than 3%, and restricting patient age to younger than 35 years may reduce the complication rate to 1%.

From Institut für Refraktive und Ophthalmo-Chirurgie, Zürich, Switzerland

Corresponding Author InformationCorresponding author: Theo Seiler, MD, PhD, Institut für Refraktive und Ophthalmo-Chirurgie (IROC), Stockerstrasse 37, CH-8002 Zürich, Switzerland.

 Dr. Mrochen has a financial interest in the UV-X device. No other author has a financial or proprietary interest in any material or method mentioned.

PII: S0886-3350(09)00481-7

doi:10.1016/j.jcrs.2009.03.035


View previous. 10 of 44 View next.